Pharmaceutical

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.

Oct 10, 2024 - 04:00
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
Read the original article

Tags:

Previous Article

City Therapeutics launches with $135m Series A funding

Next Article

Magazine: Cell and gene therapy approvals drive paradigm change in manufacturing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ILution travoprost by Glaukos for Ocular Hypertension: Likelihood of Approval

ILution travoprost by Glaukos for Ocular Hypertension: ...

Jun 20, 2024

STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

STAT+: FDA’s Peter Marks seems inclined to grant full a...

Jan 10, 2024

Teva and Biolojic enter therapeutic antibody development deal

Teva and Biolojic enter therapeutic antibody developmen...

Dec 16, 2023